目前关于囊性纤维化成人患者在调节疗法时代促进健康衰老的高影响可改变生活方式的知识、关键空白和未来研究机会。

Aging in cystic fibrosis (CF), once a hopeful possibility, is now a celebrated reality for many and attributable to expert multidisciplinary care, persistent research efforts, and fervent advocacy. The median age of survival of people with CF (PWCF) increased dramatically with the advent of cystic fibrosis transmembrane conductance regulator modulator therapies, particularly elexacaftor/tezacaftor/ivacaftor in 2019. However, as PWCF live longer, healthy aging is susceptible to the compound impact of residual CFTR dysfunction, chronic inflammation, emerging comorbidities, complexities of chroni